Patients with wet age-related macular degeneration who were treated with high-dose aflibercept experienced improvements in anatomical and vision outcomes through 44 weeks, according to a press release from Regeneron.
CANDELA, a phase 2, randomized, single-masked trial, enrolled 106 patients with wet AMD to study the efficacy, safety and tolerability of aflibercept 8 mg compared with currently approved Eylea (aflibercept 2 mg).
At week 44, 40% of patients who received aflibercept 8 mg had no fluid in the center subfield compared with 28% of patients who received aflibercept 2 mg, which (Read more...)